Circulating Endotoxin during Initial Antibiotic Treatment of Severe Gram‐Negative Bacteremic Infections | Zendy

Éric Maury | Zendy; V. Barakett | Zendy; Hervé Blanchard | Zendy; Christophe Guitton | Zendy; Catherine Fitting | Zendy; T Vassal | Zendy; Pierre Chauvin | Zendy; Bertrand Guidet | Zendy; Georges Offenstadt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Circulating Endotoxin during Initial Antibiotic Treatment of Severe Gram‐Negative Bacteremic Infections

Author(s) -

Éric Maury,

V. Barakett,

Hervé Blanchard,

Christophe Guitton,

Catherine Fitting,

T Vassal,

Pierre Chauvin,

Bertrand Guidet,

Georges Offenstadt

Publication year - 1998

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/517451

Subject(s) - interquartile range , bacteremia , sepsis , antibiotics , septic shock , medicine , shock (circulatory) , gastroenterology , tumor necrosis factor alpha , immunology , gram , microbiology and biotechnology , biology , bacteria , genetics

The impact of antibiotics on total endotoxemia and circulating tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-8 in 18 patients with severe bacteremic sepsis or septic shock due to gram-negative species was investigated. Endotoxemia, TNF-alpha, IL-6, and IL-8 were assayed before (H0) and 1 h (H1) and 4 h (H4) after the first antibiotic infusion. Endotoxemia decreased from H0 (median, 0.4 EU/mL; interquartile interval, 0.09-1.23) to H1 (median, 0.19 EU/mL; interquartile interval, 0.07-0.75; P = .03) and remained stable between H1 and H4 (median, 0.12 EU/mL; interquartile interval, 0.09-0.30; P = .4). IL-6 levels fell between H0 and H4 (P = .01) and between H1 and H4 (P = .03). IL-8 was higher at H0 than at H1 (P = .04) and at H4 (P = .01). These results suggest that endotoxemia is not increased by antibiotherapy of severe gram-negative bacteremia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research